Stockreport
Allogene Therapeutics Inc (ALLO) Q4 2025 Earnings Call Highlights: Financial Stability and ... [Yahoo! Finance]
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
This article first appeared on GuruFocus Cash, Cash Equivalents, and Investments: $258.3 million as of December 31, 2025. Additional Cash Received: $23.7 million from escrow related to Servier's arbitration outcome. ATM Equity Facility: Raised an additional $20.7 million year to date. Cash Runway: Extended into the first quarter of 2028. R&D Expenses (Q4 2025): $28.6 million, including $2.5 million of non-cash stock-based compensation. R&D Expenses (Full Year 2025): $150.2 million, including $12.9 million of non-cash stock-based compensation. G&A Expenses (Q4 2025): $13.8 million, including $5.6 million in non-cash stock-based compensation. G&A Expenses (Full Year 2025): $56.8 million, including $24.7 million of non-cash stock-based compensation. Net Loss (Q4 2025): $38.8 million, or $0.17 per share, including $8.1 million of non-cash stock-based compensation. Net Loss (Full Year 2025): $190.9 million, or $0.87 per share, including $37.6 million of non-cash stock-
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | ALLO | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
ALLO alerts
ALLO alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
NEWS
NEWS
- Allogene Therapeutics (ALLO) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $14.00 price target on the stock.[MarketBeat]
- Allogene Therapeutics (ALLO) had its price target raised by Piper Sandler from $7.00 to $8.00. They now have an "overweight" rating on the stock.[MarketBeat]
- Allogene Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance][Yahoo! Finance]
- Allogene Therapeutics GAAP EPS of -$0.17 beats by $0.05 [Seeking Alpha][Seeking Alpha]
- Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update [GlobeNewswire]
- More
ALLO
SEC Filings
SEC Filings
- 3/18/26 - Form 4
- 3/18/26 - Form 4
- 3/16/26 - Form 144
- ALLO's page on the SEC website
- More